WO2000014268A1 - Modulation du metabolisme microbien et/ou du taux de croissance au moyen d'hormones de croissance vegetales - Google Patents

Modulation du metabolisme microbien et/ou du taux de croissance au moyen d'hormones de croissance vegetales Download PDF

Info

Publication number
WO2000014268A1
WO2000014268A1 PCT/US1999/020491 US9920491W WO0014268A1 WO 2000014268 A1 WO2000014268 A1 WO 2000014268A1 US 9920491 W US9920491 W US 9920491W WO 0014268 A1 WO0014268 A1 WO 0014268A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant growth
bacteria
fungi
growth hormone
absence
Prior art date
Application number
PCT/US1999/020491
Other languages
English (en)
Other versions
WO2000014268A9 (fr
Inventor
Stephen C. Edberg
Original Assignee
Edberg Stephen C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edberg Stephen C filed Critical Edberg Stephen C
Priority to AU59110/99A priority Critical patent/AU5911099A/en
Publication of WO2000014268A1 publication Critical patent/WO2000014268A1/fr
Publication of WO2000014268A9 publication Critical patent/WO2000014268A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor

Definitions

  • Bacteria are single cell life forms that do not have a nucleus (Prokaryotes). Fungi are single celled life forms that do have a nucleus. In common they divide, or multiply, by binary fission. Essentially, the body of the microbe increases in size until a signal is generated whereby the cell is split into two. This is accomplished by doubling the genetic material, sequestering each half in opposite sides of the cell, and then dividing the cell into two parts by the laying down of a new cell wall. The cell wall is the physical outer skeleton of microbes. Each cell is called a daughter cell. Bacteria and fungi are not considered plants. However, they share with plants an anatomical structure called the cell wall.
  • the cell walls of microbes and plants are very different physically and chemically - the only commonality is that the cell wall provides external rigid structure to the cells.
  • the cell wall in bacteria, fungi, and plants provide a physically rigid shape to the living entity.
  • the microbe In bacteria and fungi, the microbe is always single-celled. Therefore, the cell wall provides the bacteria or fungi with its shape - e.g., rods, cocci, spiral.
  • the cell wall not only provides shape, but also allows compartmentalization.
  • the cell walls of bacteria and fungi are significantly different from those of plants.
  • the growth and differentiation of multi-celled organisms which have specialized structures (e.g., leaves, roots, etc.), are controlled by signals. These signals can be chemical (hormones) or electrical. Signals in protists and fungi have not been described. Each stage in the growth of a plant is controlled by endogenous plant growth regulators which function as hormones. These are known as phytohormones.
  • Plant hormones have the following properties: they are chemically characterized; they show a specific biological activity at low concentrations; they play a fundamental role in regulating plant growth or differentiation; they are generally synthesized at one site and active at another site.
  • Plant growth hormones act as chemical signals to promote growth in plants.
  • a hormone is a molecule generated in one cell that travels to a distant cell where it conveys a message, such as to turn on or to turn off a function.
  • insulin is made in the pancreas that travels to receptors throughout the body to affect the metabolism of glucose.
  • plants contain billions of cells arranged in specialized structures (e.g., roots, branches, phloem, xylem), a growth hormone which is able to act at a distance from the site of production of the hormone is necessary in order to signal plant growth.
  • Prior art which relates to increasing the yield of endproducts includes: U.S. Patent No. 5,925,807, in which a fungus is used to produce gibberellic acid, with no mention of any effect of GA on the fungus itself; U.S. Patent No. 5,002,603, which discloses a method for stimulating growth of a fungus using isoflavanoids; U.S. Patent No. 5,691,275, which discloses compositions of an alkali metal formononetinate that stimulate the growth of fungi; and U.S. Patent No. 4,911,746, which discloses the use of 1- hydroxylethylenazole compounds to regulate the growth of fungi.
  • the invention also includes a method of increasing the metabolic rate of bacteria or fungi to produce a defined product, comprising growing the bacteria or fungi in the presence of a plant growth hormone, in an amount sufficient to permit an increase in the metabolic rate of the bacteria or fungi to produce a defined product relative to the production of a defined product by bacteria or fungi grown in the absence of the plant growth hormone.
  • the invention also includes a method of increasing the growth rate of bacteria or fungi, comprising growing the bacteria or fungi in the presence of a plant growth hormone selected from the group consisting of : gibberellins, cytokinins, absciscic acids, and ethylenes, in an amount sufficient to permit an increase in the rate of growth of the bacteria or fungi relative to the rate of growth of the bacteria or fungi grown in the absence of the plant growth hormone.
  • a plant growth hormone selected from the group consisting of : gibberellins, cytokinins, absciscic acids, and ethylenes
  • the invention also includes a method of decreasing the time for detection of bacteria or fungi in a biological sample, comprising performing a detection step indicating the presence or absence of bacteria or fungi in a sample that is incubating in the presence of an amount of a plant growth hormone sufficient to permit a decrease in the time of incubation relative to the time of incubation of a sample that is incubating in the absence of the plant growth hormone.
  • the invention also includes a method of decreasing the time for detection of bacteria or fungi in a biological sample, comprising incubating the sample in the presence of an amount of a plant growth hormone sufficient to permit a decrease in the time of incubation relative to the time of incubation of a sample that is incubated in the absence of the plant growth hormone, and performing a detection step in which the presence or absence of the bacteria or fungi in the incubated sample is indicated.
  • the invention also includes a method of decreasing the time for determining antibiotic susceptibility of bacteria or fungi, comprising determining the presence or absence of bacteria or fungi that is incubating in the presence of the antibiotic and an amount of a plant growth hormone sufficient to permit a decrease in the time of incubation relative to the time of incubation of bacteria or fungi that is incubated in the absence of the plant growth hormone, the absence of the bacteria or fungi indicating antibiotic susceptibility or the presence of the bacteria or fungi indicating antibiotic resistance.
  • the invention also includes a method of decreasing the time for determining antibiotic susceptibility of bacteria or fungi, comprising incubating bacteria or fungi in the presence of an antibiotic and an amount of a plant growth hormone sufficient to permit a decrease in the time of incubation relative to the time of incubation of bacteria or fungi that is incubated in the absence of the plant growth hormone, and determining the presence or absence of the bacteria or fungi, the absence of the bacteria or fungi indicating antibiotic susceptibility or the presence of the bacteria or fungi indicating antibiotic resistance.
  • the invention also includes a method of decreasing the time for identification of bacteria or fungi in a biological sample, comprising incubating a biological sample suspected of containing a type of bacteria or fungi in the presence of an amount of a plant growth hormone sufficient to permit a decrease in the time of incubation of the bacteria or fungi relative to the time of incubation of the bacteria or fungi that is incubated in the absence of the plant growth hormone, and identifying the type of bacteria or fungi that is present in the sample.
  • the invention also includes a method of decreasing the time required for a diagnostic test involving bacteria or fungi, comprising performing a diagnostic test on bacteria or fungi while growing the bacteria or fungi in the presence of an amount of a plant growth hormone sufficient to permit a decrease in the time required to grow the bacteria or fungi relative to the time required to grow the bacteria or fungi in the absence of the plant growth hormone.
  • the invention also includes a method of decreasing the time required for a diagnostic test for bacteria or fungi, comprising growing the bacteria or fungi in the presence of an amount of plant growth hormone sufficient to permit a decrease in the time required to grow the bacteria or fungi relative to the time required to grow the bacteria or fungi in the absence of the plant growth hormone; and performing a diagnostic test on the bacteria or fungi.
  • the method is performed in the presence of a second plant growth hormone which is different from the plant growth hormone.
  • the method is performed in the presence of a bacterial or fungal resuscitator.
  • the steps preferably include incubating the bacteria or fungi in a medium in the presence of one or more PGHs, and detecting the presence of the bacteria or fungi, or alternatively, determining or measuring the amount of bacteria or fungi in the presence of the PGH. Additional steps may include comparing the amount of bacteria or fungi in the presence of PGH with the amount in the absence of PGH.
  • the invention also encompasses a composition comprising a bacterial or fungal growth medium in combination with a plant growth hormone and a bacterial or fungal resuscitator.
  • the invention also relates to a composition comprising a bacterial or fungal growth medium, a first plant growth hormone, and a second plant growth hormone that is different from the first plant growth hormone, wherein the first and second plant growth hormones are present in the medium in an amount sufficient to increase the growth rate of bacteria or fungi in their absence.
  • Plant hormones are regulators produced by plants, which in low concentrations, regulate plant physiological processes. Hormones usually move within the plant from a site of production to a site of action. (Committee of the American Society of Plant Pathologists, in Takahashi "Chemistry of Plant Hormones”. CRC press, 1986, page 10).
  • a "statistically significant decrease" in incubation time may be a 5-10% decrease or a 25%, 50%, 75%, or 100% decrease in the time of incubation required to reach a given cell density (as measured, for example, by optical density (O.D.)).
  • an “amount” in this context may be in the range of about 0.001-10 mm of PGH, for example, in a subrange of 0.01-lOmm, or 0.1-1 mm.
  • incubating may encompass incubating in liquid or solid or semi-solid (e.g., agar) medium, and therefore includes such phrases as “being grown in” or being grown on” or “cultured in” or “cultured on”.
  • “Decreasing the time for detection" of bacteria or fungi in a sample refers to a decrease in time between initiating and terminating a given assay. According to the invention, such a decrease may be at least 10% (hours, minutes, or units of time), and also may be more such as 20-50%, or even 75-95%.
  • the time for detection of bacteria or fungi in a blood culture usually requires an average of 36 hours to obtain a positive signal.
  • the invention provides for a decrease of at least about 3.6 hours and even more, e.g., 4.0 hours, 5.0 hours, 8 hours, or more.
  • Antibiotic resistance refers to the ability of a microbe to multiply in the presence of clinically useful concentrations of antibiotic.
  • an “antibiotic” is defined herein as a chemical (whether an isolated natural chemical or a synthetic chemical) that inhibits the growth and/or multiplication of a microbe, and may be present in a given medium in the range of about 0.5 ⁇ g/ml to several hundred (200) ⁇ g/ml.
  • Antibiotics useful in the invention include but are not limited to those listed in Table 7.
  • Identifying a type of bacteria or fungi refers to assigning to a microbe a useful and reproducible identifier.
  • This identifier may be a genus and species name (e.g., Enterococcus faecalis), a genus name only (e.g., Enterococcus), an antigen identifier (e.g.. Group A streptococcus), or a set of phenotypic characteristics.
  • a "type” of bacteria or fungi refers to the identifier selected.
  • “decreasing" the time for identification of bacteria or fungi refers to a decrease in time that permits assignment of an identifier.
  • “Growing” bacteria or fungi refers to incubating bacteria or fungi under conditions sufficient to permit doubling of the bacteria or fungi in a given time period, that is, an increase in the number of bacteria or fungi over time.
  • “Growth rate” or “rate of growth” refers to the doubling time of bacteria or fungi, i.e., the time period in which a given number of bacteria or fungi doubles; for example, E.coli may grow at a rate of about 1 doubling every 20 minutes under conventional growth conditions at 37°C.
  • E. coli 20 minutes, 30 minutes; Enterococcus, 30 minutes, 40 minutes; Pseudomonas aeruginosa, 30 minutes, 40 minutes; Salmonella typhimurium, 20 minutes, 40 minutes; Mycobacterium tuberculosis, 2 hours, 6 hours.
  • a “diagnostic test” refers to an assay in which a type of a microbe is identified or the presence of a microbe is determined. Some diagnostic tests do not require growth of the microbe, for example a test for production of a constitutive enzyme, where the assay time is reduced according to the invention from an average of 5 hours to an average of 4 hours; production of an inducible enzyme, e.g., where the assay time is reduced according to the invention from an average of 22 hours of incubation to an average of 20 hours of incubation.
  • a “genetically engineered bacterial cell” or a “genetically engineered fungal cell” refers to a host bacterial or fungal cell containing a recombinant or genetically engineered DNA.
  • a “product” of an “engineered gene” refers to an RNA or a protein.
  • an “increase” in the amount of product produced by a cell refers to an increase by 5-10% or more (e.g., 25%, 50%, 75%, 100% or more), or two-fold or more (e.g. 5-fold, 10-fold, 50-fold or more) of the product. Percentages refer to w/w or w/vol.
  • a microbe that is, a bacterium or fungus
  • a microbe may be directed to produce more of itself (i.e., to decrease the amount of time required to divide from one bacterium or fungal cell into two) in a shorter time period by incubating the bacteria or fungi in a medium that contains at least the minimal nutritional requirements for bacterial or fungal growth and also contains a plant growth hormone that is selected from the group consisting of: gibberellins; cytokinins; abscisic acids; and ethylenes.
  • the invention also is based on the discovery that a microbe may be directed to produce more of itself in a shorter time period by incubating the bacteria or fungi in a medium that contains at least two different plant growth hormones.
  • the invention also is based on the discovery that a microbe may be directed to increase its metabolism. Although it is possible that an increase in metabolism leads to a decrease in the generation time, this latter aspect of the invention relates to a general increase in metabolism and also an increase in metabolism with reference to increasing production of a defined product, which is distinct from and does not necessarily involve a general increase in metabolism. An increase in metabolism that increases production of a defined product preferably does not also involve an increase in growth rate, at least above a minimal level of 5-10%.
  • Treatments or factors leading to a decrease in the generation time of bacteria or fungi may be useful to include in media used to test sterility, such as for pharmaceuticals, or in the culture of blood for sepsis.
  • An increase in metabolism would be useful, for example, if one wanted to use the microbe to produce an endproduct.
  • the invention thus also is based on the discovery that the time required to perform a diagnostic or antibiotic susceptibility test or to produce a genetically engineered product of a bacterium or fungus may be significantly reduced by growth of the bacteria or fungi in a medium containing a plant hormone.
  • the invention thus also is based on the discovery that the above assays may be performed in the presence of a bacterial or fungal resuscitator and therefore media according to the invention also may include a bacterial resuscitator.
  • Bacteria and Fungi Useful According to the Invention A. Bacteria Useful According to the Invention:
  • a "bacterium” is herein defined as a protist (without an organized nucleus) that divides by binary fission. Classes and types of bacteria useful according to the invention are presented in Table 1.
  • Nitrobacteraceae flagella compounds Nitrobacter
  • Fungi are a diverse group of eukaryotes, which are currently undergoing taxonomic redefinition from parameters based primarily on phenotypic characteristics to those based on genotypic characteristics.
  • the nomenclature of fungi is governed by the International Code of Botanical Nomenclature (ICBN) as adopted by each International Botanical Congress. (Greuter, W, et. al. 1994. International code of botanical nomenclature (Tokyo Code) adopted by the Fifteenth International Botanical Congress, Yokohama, August-September 1993. Rengnum Veg. 131.
  • Basidiomycetes septate basidiospores conidia
  • Deuteromycetes septate none conidia (fungi imperfecti)
  • Table 3 presents an overview of yeast general from each of the four classes of fungi presented in Table 2.
  • Table 3 An overview of yeast genera
  • Genera (Ascmycotina) (Deuteromycotina) Genera (Basidiomycotina) Genera (Basidiomycotine
  • Botryoascus (1 ) Myxozyma (9) Fil ⁇ basidium (5) Kockovaella (2)
  • Cephaoloascus Oosporidium ( 1 ) Leucosporidium (3) Kurtzmanomyces (2)
  • Rhodosporidium Rhodotorula
  • the Yeasts A Taxonomic Study (edited by CP. Kurtzman and J.W. Fell; published by Elsevier 1997).
  • An alternative means of classifying the fungi is to examine their placement in the three major kingdoms of life: Table 4. Phyla and classes of the three kingdoms where fungi are placed.
  • yeast that is, fungal
  • fungi have been found to produce a wide variety of medicines.
  • antibiotics, anti-rejection medicine (to permit organ transplantation), etc. arise from fungi and are commercially produced by them.
  • Modern biotechnology has utilized fungi for the production of starting, or core molecules, which are subsequently modified in the laboratory for specific pharmacological reasons.
  • chemical modification of the basic penicillin molecule results in semi-synthetic antibiotics which are better absorbed, resistant to bacterial enzymes, and have better body distribution.
  • An additional area in which fungi have proven useful is for the production of biologically active molecules via genetic engineering.
  • Fungi being eukaryotic cells, have proven efficient at producing molecules that are biologically active in humans.
  • Saccharomyces cerevisiae The basic requirements for Saccharomyces cerevisiae, and most yeasts, include 3 :
  • Nitrogen Ammonium ions (such as from 3-20 g/liter
  • Saccharomyces cerevisiae may be grown in batch cultures, followed by isolation of the desired product, such as urokinase.
  • Saccharomyces cerevisiae may be continuously cultured to produce such products by a number of means to synchronize growth, as outlined in Table 6.
  • This invention can modify the growth and/or metabolism rate of fungi to increase the efficiency of production of commercial useful endproducts. Moreover, by increasing the growth and/or metabolism of fungi, the invention can increase the efficiency of producing products that require fungi to be present. Moreover, the invention can decrease the time needed to finalize the endproduct, whether the end product is a molecule or food. Fungi can also be pathogenic in humans. Their diagnosis follows the same principles as bacterial diagnosis: isolation from a specimen; detection of an antigen; detection of an antibody. After isolation, anti-fungal antibiotic susceptibility tests should be performed. The invention will make all of these steps more efficient. The invention is practiced on fungi to enhance their growth rate and/or metabolism. Plant growth hormones, in combination with each other, with or without resuscitators, are incorporated into fungal growth media. The media may be either liquid or solid.
  • a resuscitator as described herein may additionally be added to a culture containing PGHs in order to further enhance the fungal growth. Proportions will be specific to individual species of fungi and determined by the reaction of the target fungi. To identify the proportions of one or more PGHs and/or resuscitators effective to enhance the growth or metabolism of a particular fungus, a checkerboard as described below in “Combinations of PGHs Useful According to the Invention" is employed.
  • Fungal growth detection is enhanced according to the invention if there is a statistically significant decrease in the time required for signal perception in the presence of one or more PGHs relative to the time required to detect growth in the absence of PGHs.
  • Fungal metabolism is enhanced according to the invention if there is a 10% or greater increase in a measured metabolic indicator in the presence of one or more PGHs relative to the indicator in the absence of PGH.
  • Antibiotics useful according to the invention include, but are not limited to those listed in Table 7. Table 7
  • Antibiotic (mcg/mL) (mcg/mL) ampicillin 4 32 mezlocillin 8 128 amoxicillin/clavulanic acid 2/1 32/16 ticarcillin clavulanic acid 8/1 128/2 cafazolin 4 64 cephalothin 4 64 cefuroxime 4 64 cefepime 4 64 cefoxitin 4 32 ceftazidime 4 64 ceftriaxone 4 128 cefixime 0.5 8 imipenem 2 32 aztreonam 4 64 gentamicin 2 16 amikacin 8 64 tetracyline 2 32 ciprofloxicin 0.5 8 trimethoprim/sulfamethoxazole 1/19 8/152 chloramphenicol 4 64 sulfonamides 50 400 trimethoprim 2 32 Plant Growth Hormones Useful According to the Invention:
  • Plant growth hormone a general term to mean a regulatory chemical of plant and plant cell growth. These are associated with a wide variety of physiological functions in plants, and are also known as phytohormones or plant growth regulators. Plant growth hormones are naturally plant products, but can be made to be produced, via recombinant DNA techniques, by fungi and bacteria.
  • Chemical classes of plant growth regulators useful according to the invention are as follows: auxins; gibberellins; cytokinins; abscisic acids; and ethylenes.
  • Plant growth hormones include the following classes: Auxins:
  • auxin is a general term for compounds whose primary activity is to induce elongation in shoot cells. They resemble indole-3-acetic acid (IAA) in physiological action.
  • IAA indole-3-acetic acid
  • Auxins include but are not limited to the following: centrophenoxine p-chlorophenoxyacetic acid chlorogenic acid trans-cinnamic acid 2,4-dichlorophenoxyactic acid indole-3-acetic acid indole-3 -acetic acid methyl ester indole-3-acetyl-L-alanine indole-3-acetyl-L-aspartic acid indole-3-acetyl-L-phenylalanine indole-3-acetylblycine indole-3 -butyric acid indole-3 -butyrl-beta-alanine indole-3-propionic acid alpha-naphthaleneacetic acid beta-naphthoxyacetic acid phenylacetic acid picoloram 2,4,5-trichlorophenoxyacetic acid
  • Cytokinins include but are not limited to the following: adenine adenine hemisulfate 6-benzylaminopurine 6-benzylaminopurine riboside N-benzyl-9-(2-tetrahydropyranyl)adenine DL-dihyrozeatin
  • Ethylene is a gaseous substance that has growth regulating effects in higher plants.
  • Abscisic acids and other plant growth hormones include but are not limited to the following: cis,trans-abscisic acid ancymidol chlorocholine chloride 3,6-dichloro-o-anisic acid
  • IAA or heteroauxin, the broader term
  • mixed giberellic acids and zeatin or kinetic riboside alone or in combination.
  • Combinations can be with IAAxGAs; IAAxKinetins;GAsxkinetins; IAAxGAsxkinetins.
  • Any combination of PGHs which includes any combination from all five classes of PGHs, is useful according to the invention.
  • Proportions of PGHs will be particular to the specific microbe and determined by the reaction of the target microbe(s). Practically, a "checkerboard" titration is instituted in which all combinations of two given series of concentrations of two PGHs are prepared and examined for their effect on bacterial or fungal growth and/or metabolism. For example, sequential one-half dilutions of a first PGH (PGH#1) from an initial concentration of 10 mmol to a final concentration of 0.001 mmol are prepared on the X axis of the checkerboard, and sequential one-half dilutions of a second PGH (PGH#2) from an initial concentration of 10 mmol to a final concentration of 0.001 mmol are prepared on the Y axis.
  • PGH#1 sequential one-half dilutions of a first PGH (PGH#1) from an initial concentration of 10 mmol to a final concentration of 0.001 mmol are prepared on the X axis of the checkerboard
  • each axis will have concentrations of 10, 5, 2.5, 1.25, 0.625, 0.31, 0.15, 0.075, 0.037, 0.018, 0.09, 0.045, 0.0225, 0.0011, 0.0005, 0.00025, 0.000125, and 0.0000625 mmol.
  • All the test tubes that fill in the checkerboard cover the range of combinations of PGH#1 and PGH#2 useful in the invention. In addition, this checkerboard pattern is reproduced 18 times.
  • the samples containing bacteria or fungi are incubated and monitored over time for either the density of bacteria or fungi (for example, by O.D. measurement) or for the amount of an indicator product (such as I4 CO 2 ) or metabolic end product (such as glucose isomerase, or a product of genetic engineering, such as insulin or urokinase).
  • an indicator product such as I4 CO 2
  • metabolic end product such as glucose isomerase, or a product of genetic engineering, such as insulin or urokinase
  • a similar approach may be taken to determine the optimal amount of a particular resuscitator or resuscitators to further enhance the growth or metabolism of a fungal culture.
  • a fungal growth medium containing an optimal level of one or more PGHs as determined by a prior checkerboard-type titration, may be supplemented with varying concentrations of one or more resuscitators in a subsequent checkerboard-type titration, allowing the identification of the optimal concentration(s) of resuscitator(s).
  • Growth or growth detection is considered to be enhanced if there is a statistically significant decrease in the time required for signal in the presence of PGHs relative to the time required in the absence of PGHs. For a metabolic change, a 10% increase in the presence of PGH, relative to the absence of PGH, is indicative of an effect.
  • a PGH alone or in combination with another PGH of a different class or a different type in the same class, can be used in a wide variety of media formulations.
  • the basic formulation for bacterial growth medium containing one or more PGHs is to add an amount of PGHs (one or more than one PGH as a mixture) in the range of 0.001 to 10 mmol (millimole) final concentration, e.g., in the range of 0.01 to 10 mmol, or in the range of 0.1 mmol to 1 mmol.
  • the invention contemplates the addition of one or more PGHs to a bacterial growth medium, wherein the single PGH or any combination of PGHs has the effect of increasing the growth rate or metabolic rate of the bacteria in the growth medium.
  • bacterial culture media to which PGHs may be added include (mass amounts of the various components are per liter of medium): Columbia broth (used for the culture of blood) Polypeptone 10.0 grams
  • the PGHs at concentrations of 10 ppm are sterile filtered and added to the medium after autoclaving. Also after autoclaving, a carbohydrate, such as lactose is added to a final concentration of 1 percent.
  • the agar is dispensed into test tubes and allowed to harden. The top of a colony is touched with a straight bacterial wire, and stabbed into the CTA agar. Fermentation is indicated by a change in color from red to yellow.
  • fungi will grow in bacterial growth media as described above or as known in the art. Obviously, those media which contain an anti-fungal agent, such as MacConkey's agar, will not be useful for fungal growth. In addition to media originally optimized for bacterial cell growth, media optimized for fungal growth may be useful. Examples of media optimized for fungal growth are presented in Table 9.
  • Wort Broth Malt extract 15 grams Peptone 1 gram Maltose 12.75 grams Dextrin 2.75 grams Glycerol 2.35 grams Dipotassium 1 gram phosphate
  • Other fungal media include, but are not limited to Sabouraud's broth, corn meal broth, malt extract broth, malt extract dextrose broth, and yeast extract broth. All of these media are available from Difco.
  • the liquid fungal growth media can be made as solid medium with the addition of approximately 20 grams of agar per liter to the final mixture.
  • Plant growth hormones of the same types and in the same range of concentrations described herein for enhancing bacterial growth and/or metabolism are useful for enhancing fungal growth and/or metabolism. That is, a PGH, alone or in combination with another PGH of a different class or a different type in the same class, can be used in a wide variety of fungal growth media formulations.
  • the basic formulation for fungal growth medium containing one or more PGHs is to add an amount of PGHs (one or more than one PGH as a mixture) in the range of 0.001 to 10 mmol (millimole) final concentration, e.g., in the range of 0.01 to 10 mmol, or in the range of 0.1 mmol to 1 mmol.
  • the invention contemplates the addition of one or more PGHs to a fungal growth medium, wherein the single PGH or any combination of PGHs has the effect of increasing the growth rate or metabolic rate of the fungi in the growth medium.
  • resuscitators are compounds either made by the microbe or obtained from the environment. Generally, they are naturally occurring, although chemical analogs may be effective. Resuscitators may assist in the metabolism or recovery of both bacteria and fungi. Examples of resuscitators useful according to the invention include but are not limited to [% or units referred to are in final concentrations in media]: intermediary metabolites such as sodium pyruvate: 0.001 to 1.0% catalase: 100 to 4000 Units acetic acid: 0.001 to 0.1% water soluble vitamins, particularly the B vitamin group:0.001 to 1.0% hemin: 0.001 to 0.01% and combinations of the above.
  • intermediary metabolites such as sodium pyruvate: 0.001 to 1.0% catalase: 100 to 4000 Units acetic acid: 0.001 to 0.1% water soluble vitamins, particularly the B vitamin group:0.001 to 1.0% hemin: 0.001 to 0.01% and combinations of the above.
  • the invention encompasses the following methods and compositions without limitation thereto.
  • PGHs plant growth hormones
  • fever workup When a patient develops fever and is either in, or admitted to, a hospital it is routine to do a "fever workup".
  • the fever workup almost always includes obtaining blood and inoculating that blood in microbial growth medium.
  • the physician wishes to establish if the patient has sepsis, which is serious and can also result in the seeding of organs.
  • a sterility test of the patient's blood is performed.
  • blood from the patient is inoculated into liquid growth medium.
  • the liquid growth medium is incubated at 35-37°C. Periodically it is examined for evidence of microbial activity.
  • Microbial activity may be monitored by: visual observation (or by examining changes in optical absorbance); monitoring for the production of 14 CO 2 ; or by the change in a fluorescent indicator attached to the bottle holding the growth medium. Once evidence of microbial activity is noted, a sample from the blood culture bottle is removed and analyzed to determine which type of microbe is present (e.g., bacterium or fungus, gram positive or gram negative). The physician is notified by telephone, since microbial growth is considered a medical emergency.
  • type of microbe e.g., bacterium or fungus, gram positive or gram negative
  • one or more PGHs are added to the blood culture medium. For example, from 0.001 to 10 mmol [millimole] final concentration of IAA alone, and with 0.001 to 10 mmol mixed gibberellic acids, and with 0.001 mmol of kinetic riboside, is added to the blood culture bottles. These are compared with samples to which blood sample, but no PGHs are added. Patients are sampled so that there are 50 with sepsis. In the bottles with the PGH(s), there is a statistically significant reduction of the average time of detection of microbial growth.
  • antigens are useful, and economically important, in a number of fields including, but not limited to production of vaccines (antigens are purified and inoculated into people to produce antibody - for example, tetanus toxoid, diphtheria toxoid, meningitis vaccine, and Hemophilus influenzae b [Hib]), and the identification of bacteria or fungi in the clinical laboratory (a bacterial or fungal colony is mixed with antisera specific for a variety of bacteria or fungi; if there is a reaction with one, the bacterium or fungus is identified).
  • vaccines antigens are purified and inoculated into people to produce antibody - for example, tetanus toxoid, diphtheria toxoid, meningitis vaccine, and Hemophilus influenzae b [Hib]
  • identification of bacteria or fungi in the clinical laboratory a bacterial or fungal colony is mixed with antisera specific for a variety of bacteria or
  • PGHs are added to the liquid culture medium. For example, from 0.001 to 10 mmol [millimole] final concentration of IAA alone, and with 0.001 to 10 mmol mixed gibberellic acids, and with 0.001 mmol of kinetin riboside or zeatin, is added to the liquid culture medium.
  • the optimal concentrations of PGH(s) is determined, for example, by performing a "checkerboard" titration as described in the section "Combinations of PGHs Useful According to the Invention".
  • the microbe is grown in a chemostat, in which fresh medium is slowly pumped into a vessel, and an equal amount of spent culture medium is simultaneously removed. With the spent culture medium is the microbe, and the antigen. The more antigen leaving with the spent medium, the more commercially viable the process. A comparison of chemostats with and without PGHs will show at least a 10% increase in antigen yield.
  • a genetically engineered bacterium or fungus produces a useful product.
  • the clone grows in liquid medium, generally in a chemostat type device (new medium is added, old medium with the desired product is removed). In this case, one wishes to increase the metabolism of the clone, not its numbers.
  • the addition of one or more plant growth hormones increases the end product by at least 5%.
  • bacteria or fungi such as yeast
  • a bacterium or fungal cell which is changed by manipulating its DNA is called "genetically engineered”.
  • These bacteria or fungi are constructed by inserting plasmids or genetic elements that code for the production of a particular commercial product into the chromosome.
  • natural bacteria or fungi that make small amounts of the desired endproduct are manipulated to produce more. They may be subjected to ultraviolet light or mutagens.
  • Glucose Isomerase This enzyme catalyzes the conversion of glucose to fructose.
  • Fructose is the major sugar used in food processing.
  • the cost of production of the enzyme is an important factor in valuation of its suitability for industrial application. Intensive efforts have been made to optimize the fermentation parameters for the production of GI with a view to developing an economically feasible technology. Research is focused on three major aspects: (i) improvement of the yields of GI, (ii) optimization of the fermentation medium....(iii) immobilization of the enzyme.” [Bhosale SH, Rao MB, Deshpande, VV. 1996.
  • D-Glucose/xylose isomerase (D-xylose ketol isomerase; EC 5.3.1.5), commonly referred to as glucose isomerase (GI), is one of the three highest tonnage value enzymes, amylase and protease being the other two. It catalyzes the reversible isomerization of D-glucose and D-xylose to D-fructose and D-xylulose, respectively. Isomerization of glucose to fructose is of commercial importance in the production of high-fructose corn syrup. GI catalyzes the isomerization of both glucose and xylose.
  • GI catalyzes the isomerization of both glucose and xylose.
  • the yields of GI from various potent producer organisms range from 1,000 to 35,000 U liter 1 . Further improvement in the yield and the properties of the enzyme may be achieved by strain improvement, using either conventional mutagenesis or recombinant DNA technology. Further improvement of yield is obtained according to the invention using conventional growth media and a combination of PGHs.
  • GI is generally produced by submerged aerated fermentation.
  • a plant growth hormone is sterile filtered and added to the medium in the chemostat at a concentration of about 10 ppm for each plant growth hormone added. If more than one plant growth hormone is added, then each plant growth hormone should be present at about at least 10 ppm in the medium.
  • Culture medium may be prepared as follows (amounts are per liter of medium): starch lOg; potassium nitrate 2g; sodium chloride 2g; magnesium sulfate 0.05g; calcium carbonate 2g; ferric sulfate O.Olg; in 10 mmol Hepes buffer made in distilled water. After mixing, 2 grams of agar is added and autoclaved. To this medium is added 10 grams of filter sterilized glucose. If one wishes to exclude fungi, 100 mcg/mL of nystatin is added.
  • Microbial isolates, soil sample, etc. are plated on the surface of the agar. Colonies are harvested after 24 hours. GI is assayed from the cells by assaying for the production of fructose (Kulka, RG. 1956. Colorimetric estimation of ketopentoses and ketohexoses. Biochem. J. 63:542-548).
  • PGHs are added to the liquid culture medium.
  • 0.001 to 10 mmol [millimole] final concentration of IAA alone, and with 0.001 to 10 mmol mixed gibberellic acids, and with 0.001 mmol of kinetin riboside or zeatin is added.
  • the following example describes growth of bacteria using a combination of resuscitators and PGHs for the recovery of chlorine damage coliforms from drinking water.
  • Combinations of PGHs and resuscitators are added, following the protocol described in the section "Combinations of PGHs Useful According to the Invention". One looks for a statistically significant increase in recovery of injured coliforms.
  • TDB Trypticase soy broth
  • mixed gibberellic acids were added to produce final concentrations of 50; 6.25; 0.75 mcg/mL; and a negative control lacking gibberellic acids.
  • Incubation was at 35 °C.
  • TSB tubes were placed in a Spectronic 20 spectrophotometer and O.D. measured at 560 nm.
  • Klebsiella pneumoniae was isolated from a drinking water sample. It was grown overnight in trypticase soy broth (TSB) and diluted in normal saline to 10 5 /mL using spectrophotometer absorption. Colony counts were made on MacConkey's agar using quantitative loops of volume 0.01 mL on one half of the plate and 0.001 mL on the other side of the plate.
  • TTB trypticase soy broth
  • Zeatin was obtained from Sigma. It was first dissolved in ethanol and then subsequently diluted in distilled water.
  • Trypticase soy broth (TSB) was used as the basic growth medium. To TSB, Zeatin was added to produce final concentrations of 50; 6.25; 0.75 mcg/mL; and a negative control lacking zeatin. Incubation was at 35 °C. TSB tubes were placed in a Spectronic 20 spectrophotometer and Optical Density (O.D.) measured at 560 nm.
  • O.D. Optical Density
  • the base medium consisted of ammonium sulfate (5 grams/Liter) as the nitrogen source; glucose (5 grams/Liter); calcium chloride (10 mg/Liter); and magnesium sulfate (10 mg/Liter).
  • DM was made with the following additives: 20 mg/L of mixed gibberellins + 20 mg/mL kinetin (GK); 50 mg/1 of IAA + 20 mg/L of mixed gibberellins (IG); and 20/20 mg/L mixed gibberellin+kinetin+50mg/L IAA (GKI).
  • Test tubes were placed in a Spectronic 20 spectrophotometer and O.D. was measured at 560 nm.
  • n log N2-logNl 0.301
  • n generation time difference
  • N turbidity value
  • the generation time of Klebsiella pneumoniae was significantly less in the presence of PHGs than without it.
  • the base medium consisted of trypticase soy broth (TSB). To this broth, kinetin was added at a concentration of 10 mg/Liter and 20 mg/Liter and mixed Gibberellic acids at 10 mg/Liter and 20 mg/Liter. A control lacking PGHs was also inoculated. Incubation was at 35 °C. TSB tubes were placed in a Spectronic 20 spectrophotometer and O.D. was measured at 560 nm. P T/US99/20491
  • the generation time of E. coli was significantly less in the presence of mixed phytohormones than without it.
  • Phytohormones included IAA, kinetin, and mixed gibberellin.
  • E. coli was ATCC 25922.
  • Glucose was made at 5 grams/liter into 5 grams/liter of proteose peptone #3 (does not contain sugar) to which 0.2% of bromocresol purple was added.
  • Bromocresol purple is blue/purple at a basic pH and turns yellow in the presence of the acid produced by the fermentation of sugar.
  • Sorbitol at 5 grams/liter was made in the same pp#3 solution.
  • Test media were made with the following additives: 20mg/L of mixed gibberellin + 20mg/ml kinetin (GK); 50mg/L of I AA + 20mg/L of mixed gibberellin (IG); and 20/20 mg/L mixed gibberellin + kinetin + 50 mg/L IAA (GK).
  • GK mixed gibberellin + 20mg/ml kinetin
  • IG mixed gibberellin
  • GK 20/20 mg/L mixed gibberellin + kinetin + 50 mg/L IAA
  • AST antibiotic susceptibility test
  • the basic principle of the AST is that the test bacterium is inoculated into culture medium with and without antibiotic. After incubation, the growth of the bacterium in both culture media is compared. If growth in the presence of the antibiotic is significantly less compared to growth observed in culture medium without antibiotic, the test bacterium is considered susceptible to that antibiotic. If the growth of the test bacterium in the presence of the antibiotic is not significantly different from growth in the culture medium without antibiotic, the test bacterium is considered resistant.
  • test bacterium in culture medium There are a number of ways known in the art to measure the growth of the test bacterium in culture medium. Examples include measuring turbidity in liquid medium or on solid agar; measuring metabolism of a vital dye such as resazurin or tetrazolium salts; measuring production of acid from a sugar, etc.
  • Phytohormones used in this example included IAA, kinetin, and mixed gibberellins.
  • the test bacteria were E. coli ATCC 25922 and Staphyloccocus aureus ATCC 25923.
  • the antibiotic gentamicin (gm) was added to MHBR to produce a final concentration of 4 mcg/mL (MHBRgm).
  • MHBR and MHBRgm were separately dispensed into 12x75mm test tubes, 1 mL per test tube.
  • MHBR and MHBRgm was made with the following additives: 20 mg/L of mixed gibberllins + 20 mg/mL kinetin; 50 mg/L of IAA; and 20/20 mg/L mixed gibberellins+kinetin+50mg/L IAA.
  • test bacteria were diluted using a Spectronic 20 to a concentration of 10 bacteria/mL.
  • Fungi e.g., Saccharomyces cerevisiae
  • Fungi which are genetically engineered to produce urokinase
  • Urokinase is a mammalian protein that plays a central role in the blood-clotting mechanism. It is administered to patients to dissolve blood clots. Urokinase has separate sites responsible for binding to the blood clot and protease activity to dissolve the blood clot.
  • a clone of Saccharomyces cerevisiae constructed by introducing a plasmid that codes for the following characteristics: BamHlCUP 1 promoter site; ampicillin resistance; urokinase coding sequence; ubiquitin regulator genes; and G protein recognition genes is used (see Ecker, D.J. et al., 1989. Increasing gene expression in yeast by fusion to ubiquitin. J. Biol. Chem. 264: 7715-7719.).
  • the Saccharomyces cerevisiae strain bearing the urokinase plasmid is grown in synthetic medium as described above, with the addition of 100 uM CuSO 4 to induce expression.
  • Saccharomyces cerevisiae cells After shaking for 2 to 3 hours at 30°C, the Saccharomyces cerevisiae cells are centrifuged, washed, and resuspended in buffer to lyse them (50mM Tris, pH 7.6 with 10 mM dithiothreitol (a reducing agent) and 1% sodium dodecyl sulfate (SDS, a detergent)).
  • the active urokinase can be isolated by removing the salts from the proteins, by dialysis, or other means that separate proteins from salts.
  • the production of urokinase by genetically altered yeast cells may be enhanced by adding one or more PGHs, with or without a resuscitator, to the culture medium in a concentration ranging from 0.001 to 10 mmol.
  • concentration and combination of PGHs effective to enhance the production of urokinase may be determined through titrations as described herein in the section "Combinations of PGHs Useful According to the Invention".
  • Enhancement of urokinase production is determined by comparison of the amount of urokinase produced by cells grown in the absence of PGHs and/or resuscitators with the amount produced by cells grown under the same conditions and for the same amount of time but in the presence of PGHs and or resuscitators.
  • a statistically significant increase, preferably 10% or more, in the amount of urokinase produced in the presence of PGHs and/or resuscitators relative to the absence of such factors indicates an effect by the PGHs and/or resuscitators according to the invention.
  • Isoflavanoids are commercially and medically important biological products naturally produced by plants and some fimgi. Isoflavanoid compounds may be used as the synthetic starting point for the production of commercially useful compounds, or may be useful in their own right as, for example, immunosuppressants, antibiotics, antioxidants, or as drugs to treat or prevent diseases ranging in severity from baldness to cancer. Isoflavanoids can be produced by the fungus Glomus interadices in a defined medium consisting of: (amounts are in mg/liter) KN0 3 610
  • Glomus interadices may be cultured in the above defined medium at temperatures ranging from 35-43°C and at an optimal pH of 7 (pH of about 6 to about 8 is acceptable). Isoflavanoids produced by the fungus may be quantitated by nuclear magnetic resonance or by mass spectroscopy. To enhance the production of isoflavanoids by Glomus interadices, the fungus is inoculated into the defined medium in the presence of one or more PGHs either with, or without resuscitators.
  • Titrations as described herein may be used to determine the optimal concentrations (final concentrations from 0.001 to 10 mmol will generally be effective) and combination (IAA plus GAs, or GAs plus zeatin, for example) of PGHs and/or resuscitators effective to enhance the production of isoflavanoids by this fungus.
  • Enhanced production of isoflavanoids according to the invention is determined by comparing the amount of isoflavanoids produced in the presence of PGHs with the amount produced in the absence of PGHs.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé servant à accroître le taux métabolique de bactéries ou champignons, afin d'obtenir un produit déterminé, ce procédé comprenant l'étape consistant à faire croître les bactéries ou champignons en présence d'une hormone de croissance végétale en dose suffisante pour permettre un accroissement du taux métabolique de ces bactéries ou champignons et obtenir un produit déterminé par rapport à la production d'un produit déterminé par des bactéries ou champignons que l'on a fait croître en l'absence de ladite hormone de croissance végétale. L'invention concerne également un procédé d'accroissement du taux de croissance des bactéries ou champignons, lequel procédé comprend l'étape consistant à faire croître les bactéries ou champignons en présence d'une hormone de croissance végétale choisie dans le groupe constitué par des gibbérellines, des cytokinines, des acides abscissiques et des éthylènes, en dose suffisante pour permettre un accroissement du taux de croissance de ces bactéries ou champignons par rapport au taux de croissance de ceux-ci en l'absence de ladite hormone de croissance.
PCT/US1999/020491 1998-09-08 1999-09-07 Modulation du metabolisme microbien et/ou du taux de croissance au moyen d'hormones de croissance vegetales WO2000014268A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59110/99A AU5911099A (en) 1998-09-08 1999-09-07 Modulation of microbial metabolism and/or growth rate by plant growth hormones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14920398A 1998-09-08 1998-09-08
US09/149,203 1998-09-08

Publications (2)

Publication Number Publication Date
WO2000014268A1 true WO2000014268A1 (fr) 2000-03-16
WO2000014268A9 WO2000014268A9 (fr) 2000-08-17

Family

ID=22529218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020491 WO2000014268A1 (fr) 1998-09-08 1999-09-07 Modulation du metabolisme microbien et/ou du taux de croissance au moyen d'hormones de croissance vegetales

Country Status (2)

Country Link
AU (1) AU5911099A (fr)
WO (1) WO2000014268A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151772A1 (fr) * 2009-06-27 2010-12-29 Pilots Point Llc Procédé et réactifs pour détecter la présence ou l'absence d'une substance cible dans un échantillon de test
WO2011119739A1 (fr) * 2010-03-23 2011-09-29 Pilots Point Llc Procédé et milieu pour accélérer la croissance d'un analyte cible dans un échantillon d'essai

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2822433A1 (de) * 1978-05-23 1979-12-20 Peters Hans Volker Dipl Biolog Mittel zum verringern bis aufheben der resistenz von bakterien gegen chemotherapeutika und verwendung von pflanzenwuchsstoffen hierzu
GB2195657A (en) * 1983-08-24 1988-04-13 Nippon Paint Co Ltd Medium for lichen cultivation and its use
US4945059A (en) * 1986-10-02 1990-07-31 Kyowa Hakko Kogyo Co., Ltd. Method of proliferating vesicular-arbuscular mycorrhizal fungi

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2822433A1 (de) * 1978-05-23 1979-12-20 Peters Hans Volker Dipl Biolog Mittel zum verringern bis aufheben der resistenz von bakterien gegen chemotherapeutika und verwendung von pflanzenwuchsstoffen hierzu
GB2195657A (en) * 1983-08-24 1988-04-13 Nippon Paint Co Ltd Medium for lichen cultivation and its use
US4945059A (en) * 1986-10-02 1990-07-31 Kyowa Hakko Kogyo Co., Ltd. Method of proliferating vesicular-arbuscular mycorrhizal fungi

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AL-MUDHAFFAR S.: "The Effect of Indole Acetic Acid and Indole Butyric Acid on Saccharomyces cerevisiae, Cellvibrio gilvus and Aerobacter aerogenes", EGYPT. J. PHYSIOL. SCI., vol. 2, no. 1-2, 1975, pages 9 - 15, XP002927121 *
BAREA ET AL.: "A Rapid Microbiological Assay Method for Auxins, Gibberellic Acid and Kinetin Using Yeast", JOURNAL OF APPLIED BACTERIOLOGY, vol. 37, no. 1, 1974, pages 171 - 174, XP002927125 *
BIOL. VESTN., vol. 25, no. 1, 1977, pages 15 - 18 *
DATABASE CA ON STN POHLEVEN ET AL.: "Synergistic Effect of Indoleacetic Acid and Kinetin in the Mycorrhizal Fungus Suillus variegatus" *
EL-BAHRAWI S.: "Effect of Gibberellic Acid on some Microbial Growth and Spore Germination of some Fungi", ZBL. MICROBIOL., vol. 137, 1982, pages 238 - 240, XP002927123 *
FARAG ET AL.: "Growth and Aflatoxin Production by Aspergillus parasiticus in a Medium Containing Plant Hormones, Herbicides or Insecticides", JOURNAL OF FOOD PROTECTION, vol. 50, no. 12, December 1987 (1987-12-01), pages 1044 - 1047, XP002927124 *
MISKE ET AL.: "Changes of Protein Level in Cells of some Epiphytic Bacteria depending on the Dose of Phytohormones in Growth Medium", LATVIJAS PSR ZINATNU AKADEMIJAS VESTIS, no. 9, 1972, pages 113 - 118, XP002927122 *
REYES ET AL.: "Influence of Medium Composition and Plant Growth Regulators on the Mycelial Growth of Collybia Reinakeana", TOKYO NOGYO DAIGAKU NOGAKU SHUHO, vol. 43, no. 1, 1998, pages 43 - 50, XP002927127 *
WEETE ET AL.: "Effects of Plant Hormones on the Growth and Pigmentation of Epicoccum nigrum and Helminthosporium tetramera", JOURNAL OF THE ALABAMA ACADEMY OF SCIENCE, vol. 47, no. 2, 1976, pages 103 - 108, XP002927126 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151772A1 (fr) * 2009-06-27 2010-12-29 Pilots Point Llc Procédé et réactifs pour détecter la présence ou l'absence d'une substance cible dans un échantillon de test
WO2011119739A1 (fr) * 2010-03-23 2011-09-29 Pilots Point Llc Procédé et milieu pour accélérer la croissance d'un analyte cible dans un échantillon d'essai

Also Published As

Publication number Publication date
WO2000014268A9 (fr) 2000-08-17
AU5911099A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
Zheng et al. E ndomicrobium proavitum, the first isolate of E ndomicrobia class. nov.(phylum E lusimicrobia)–an ultramicrobacterium with an unusual cell cycle that fixes nitrogen with a G roup IV nitrogenase
US6046021A (en) Comparative phenotype analysis of two or more microorganisms using a plurality of substrates within a multiwell testing device
US6472201B1 (en) Comparative phenotype analysis
Ridgway et al. Unbalanced growth of yeast due to inositol deficiency
US10053744B2 (en) Yeast strain with high yield of glutathione
CN116478878A (zh) 一种高产核黄素的枯草芽孢杆菌及其应用
CN114286858A (zh) 叶酸生产菌株及其制备和应用
CN102286606A (zh) 克罗诺杆菌肉汤培养基及检测方法
CN108467879B (zh) 一种用于红霉素发酵的合成培养基
EP1616018A1 (fr) Methode de production de 1,2-propandiol au moyen de i klebsiella pneumoniae /i
CN110904016A (zh) 一株重离子诱变类球红细菌高产辅酶q10的菌株及其应用
WO2000014268A1 (fr) Modulation du metabolisme microbien et/ou du taux de croissance au moyen d'hormones de croissance vegetales
WO2023016387A1 (fr) Bacillus amyloliquefaciens et son utilisation dans la préparation de 1-désoxynojirimycine
US3071518A (en) Method of increasing metabolic product yield of organisms
CN112980715A (zh) 一株枯草芽孢杆菌株b13及其应用
CN113215064B (zh) 一株产美沙达唑类化合物的黏细菌及其应用
US20070099259A1 (en) Electrochemical assay for the identification of microorganisms
EP0445129A1 (fr) Procede permettant de produire le phenyl acetyl carbinol (pac), des micro-organismes utiles a cette fin et un procede de preparation de ces micro-organismes
US6342377B1 (en) Microorganisms producing 5-aminolevulinic acid and processes for producing 5-aminolevulinic acid by using the same
WO2022033084A1 (fr) Souche de firmicutes présentant une activité anticancéreuse et son utilisation contre le cancer
CN115960068B (zh) 一种具有免疫抑制活性的色酮类化合物及其制备方法和应用
Colson et al. [81] Systems for membrane alteration: Genetic perturbations of mitochondria in a “Petite-Negative” yeast
JP7424989B2 (ja) Ｍｅｔｈａｎｏｍａｓｓｉｌｉｉｃｏｃｃａｌｅｓ目の古細菌の単離及び純粋培養
JP2779079B2 (ja) ペントースの選択発酵方法
Promee Influence of heat shock and osmotic stresses on the growth and viability of Candida shehatae var shehatae and explore its probiotic potentiality

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-52, DESCRIPTION, REPLACED BY NEW PAGES 1-46; PAGES 53-59, CLAIMS, REPLACED BY NEW PAGES 47-53; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase